These British Association for Psychopharmacology guidelines cover the range and aims of treatment for anxiety disorders. They are based explicitly on the available evidence and are presented as recommendations to aid clinical decision making in primary and secondary medical care. They may also serve as a source of information for patients and their carers. The recommendations are presented together with a more detailed review of the available evidence. A consensus meeting involving experts in anxiety disorders reviewed the main subject areas and considered the strength of evidence and its clinical implications. The guidelines were constructed after extensive feedback from participants and interested parties. The strength of supporting evidence for recommendations was rated. The guidelines cover the diagnosis of anxiety disorders and key steps in clinical management, including acute treatment, relapse prevention and approaches for patients who do not respond to first-line treatments.
| Identifer | oai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:26469 |
| Date | January 2005 |
| Creators | Baldwin, David S., Anderson, Ian M., Nutt, David J., Bandelow, Borwin, Bond, Alyson, Davidson, Jonathan R. T., den Boer, Johan A., Fineberg, Naomi A., Knapp, Martin, Scott, Jan, Wittchen, Hans-Ulrich |
| Publisher | SAGE Publications Ltd |
| Source Sets | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Language | English |
| Detected Language | English |
| Type | doc-type:article, info:eu-repo/semantics/article, doc-type:Text |
| Source | Journal of Psychopharmacology, Bd. 19 (2005), Nr. 6, S. 567 - 596, ISSN: 0269-8811 |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | 10.1177/0269881105059253, 0269-8811 |
Page generated in 0.0015 seconds